Medical Education
From 2000 to 2007, Dr. Jens Nolting completed his medical studies at the Albertus Magnus University of Cologne. During his studies, he gained extensive international clinical and scientific experience at institutions including the Royal Infirmary of Edinburgh, El Hospital Costa del Sol in Spain, and St. Luke’s Hospital in Malta. Particularly formative for his later specialization in translational and immune-based oncology were his stays at Hospital Civil Guadalajara and the National Cancer Institute in Mexico, as well as the renowned Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in the USA.
Clinical Career
2007–2016
Dr. Jens Nolting completed his specialist clinical training at the Department of Hematology, Oncology, and Rheumatology at the University Hospital Bonn and at the Center for Integrated Oncology (CIO) Cologne/Bonn, a leading Comprehensive Cancer Center. There, he earned his specialist certifications in Internal Medicine, Hematology, and Oncology.
In 2013, he took on the leadership role as Principal Investigator at the Myeloma Research Center Bonn (MRCB), where he coordinated interdisciplinary research projects with industry-funded support from companies such as Celgene and Janssen Cilag.
Since 2017, Dr. Nolting has served as an oncologist at Hallwang Clinic.
Specialization
Dr. Nolting combines clinical excellence with translational research and is recognized as a distinguished expert in the fields of immuno-oncology, cancer immunology, and molecular oncology. He has a particular interest in the research and development of personalized, immune-based cancer therapies that specifically address the biological characteristics of individual tumors. His focus lies on the complex interactions within the tumor microenvironment and the role of regulatory T-cells in cancer defense. With his integrative approach, Dr. Nolting unites clinical experience and scientific innovation to develop and translate new therapeutic strategies for hematological diseases and solid tumors into practice.
Research
Dr. Jens Nolting has cultivated a long-standing, internationally shaped research career with a particular focus on the immunobiology of cancer.
Early in his studies, from 2002 to 2003, he was involved in experimental projects on molecular stem cell biology and pediatric oncology at institutions including the University Hospital Cologne and the Heinrich Heine Institute Düsseldorf. As part of his doctoral thesis from 2003 to 2006, he investigated the role of the tumor-specific antigen PRAME in neuroblastoma cells.
From 2007 to 2009, Dr. Nolting worked as a postdoctoral researcher at the Dana-Farber Cancer Institute of Harvard Medical School. There, in the renowned Laboratory for Cancer Immunology and AIDS under the direction of Prof. Dr. Dr. h.c. Harald von Boehmer, he investigated fundamental mechanisms of T-cell regulation. He gained further research experience at Johns Hopkins Hospital in Baltimore in the working group of Prof. Dr. Arceci, a renowned expert in pediatric oncology.
In 2013, Dr. Nolting was admitted to the German Research Foundation’s Collaborative Research Center 832, which focused on the molecular modulation of the tumor microenvironment. In the same year, he took over the leadership of the Myeloma Research Center Bonn (MRCB), where he was responsible for industry-funded research collaborations with Celgene and Janssen and significantly contributed to the development of innovative immunotherapies.
Publications
Dr. Jens Nolting has authored numerous scientific publications in high-ranking specialist journals, reflecting his interdisciplinary expertise and focus on immuno-oncology. His work has appeared in publications such as Nature Immunology, Immunity, Journal of Experimental Medicine, Leukemia, Cancer Immunology, Immunotherapy, and Translational Oncology.
His contributions span topics from the role of regulatory T-cells in tumor defense and mechanisms of the tumor microenvironment to innovative drug approaches for various cancer types, including multiple myeloma, melanoma, pancreatic, breast, and ovarian cancer.Of particular note is his co-authorship on an Immunity study concerning β2-microglobulin and the NLRP3 inflammasome in tumor-associated macrophages, as well as his research on BET inhibitors, CDK5, and liposomal curcumin analogs as new therapeutic options. This work makes a significant contribution to the development of targeted and immune-based therapies in modern oncology.
Awards
2013: Else Kröner-Fresenius Foundation Scholarship
1999: Foundation Chemistry Award
Additionally, Dr. Nolting has received peer-reviewed funding from Bonfor, the German Research Foundation (DFG), and the Else Kröner Research Foundation – a testament to his scientific excellence and innovative power.